The momentum built in Berlin does not end here. Targeting Phage Therapy 2025 confirmed that the field has reached a turning point, where clinical reality, regulatory structure, and industrial engagement are beginning to align.
Building on this foundation, Targeting Phage Therapy 2026 in Valencia, Spain, will focus on the next essential step: making phage therapy operational, accessible, and scalable.
While Berlin highlighted progress and proof of concept, Valencia will be about implementation. It will address how phage therapy can move into routine clinical practice, how production and regulation can keep pace with innovation, and how applications in health, animal care, food, and industry can be responsibly expanded.
The 2026 edition will bring together clinicians, scientists, regulators, and industrial partners with a shared objective: turning scientific advances into real-world solutions. From microbiota-driven precision approaches to GMP production, from regulatory harmonization to innovation pipelines, Valencia will be the place where strategy meets execution.
As we move toward a post-antibiotic era, Valencia 2026 aims to be a milestone moment, not just to discuss the future of phage therapy, but to actively shape it.
I look forward to welcome you in lovely Valencia.
Sandra Sevilla,
President of Phage Therapy 2026